ADMA Biologics to Report First Quarter 2021 Financial Results on May 12, 2021

ADMA Biologics will announce its financial results for Q1 2021 on May 12, 2021, after market close.

Rhea-AI Summary

ADMA Biologics will announce its financial results for Q1 2021 on May 12, 2021, after market close. The event will include a conference call at 4:30 p.m. ET to discuss financial performance and company updates. ADMA specializes in plasma-derived biologics for immunodeficient patients, holding FDA approvals for three products: ASCENIV™, BIVIGAM®, and NABI-HB®. The call can be accessed via phone or audio webcast, with availability for an archived recording soon after.

Argus Session date unavailable

-5.41% session move Open Argus

Details

News Market Reaction – ADMA

The recorded move for ADMA in the trading session of this news was -5.41%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference Call Scheduled for May 12, 2021 at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the first quarter ended March 31, 2021 on Wednesday, May 12, 2021 after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other company updates.

To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 1063675. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA Bio Centers subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:

Skyler Bloom

Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:

Sam Martin

Managing Director, Argot Partners | 212-600-1902 | sam@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ADMA announce its Q1 2021 financial results?

ADMA will announce its Q1 2021 financial results on May 12, 2021, after the U.S. financial markets close.

What time is the ADMA Q1 2021 earnings call?

The earnings call for ADMA's Q1 2021 results is scheduled for May 12, 2021, at 4:30 p.m. ET.

How can I access the ADMA earnings conference call?

The ADMA earnings conference call can be accessed by dialing (855) 884-8773 for local calls or (615) 622-8043 for international calls, or through a live audio webcast on the company’s investor website.

What products does ADMA Biologics manufacture?

ADMA Biologics manufactures ASCENIV™, BIVIGAM®, and NABI-HB®, which are FDA-approved plasma-derived biologics for treating immune deficiencies.